Novartis hid manipulated data about its $2 million gene therapy Zolgensma from the FDA; US District Judge Kristine Baker granted a preliminary injunction preventing Arkansas from enforcing 3 abortion restrictions; a federal judge in Ohio expressed support for a plan by attorneys representing cities and counties suing US opioid manufacturers and distributors that would bring every US community into their settlement talks despite objections from most states.
Novartis hid manipulated data about its $2 million gene therapy Zolgensma from the FDA, the agency reported. The concealment occurred while the company was applying for approval for the treatment for spinal muscular atrophy, then delayed reporting the issue, the agency said. The inaccurate data involved testing in mice of 2 different strengths of the treatment and did not affect the safety or efficacy of the treatment, but had the agency known about the issue, it would have delayed approval.
US District Judge Kristine Baker granted a preliminary injunction preventing Arkansas from enforcing 3 abortion restrictions, The Associated Press reported. They include a measure prohibiting abortion at 18 weeks, a requirement that physicians performing abortions be board-certified or board-eligible in obstetrics and gynecology, and the third prohibits doctors from performing an abortion if it’s being sought because the fetus was diagnosed with Down syndrome.
A federal judge in Ohio expressed support for a plan by attorneys representing cities and counties suing US opioid manufacturers and distributors that would bring every community nationally into their settlement talks despite objections from most states. US District Judge Dan Polster said the idea could allow the defendants accused of fueling the opioid crisis in nearly 2000 lawsuits before him the ability to obtain “global peace.” Reuters said the proposal calls for creating a class of up to 3000 counties and 30,000 municipalities that could vote on whether to accept any settlement the plaintiffs reach with defendants. Bloomberg reported that 3 of the companies—McKesson, Cardinal Health, and AmerisourceBergen—have offered $10 billion to settle claims; the National Association of Attorneys General, on behalf of 35 states, want $45 billion.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More